RESUMEN
Human norovirus was discovered more than five decades ago and is a widespread cause of outbreaks of acute gastroenteritis. There are no approved vaccines or antivirals currently available. However, norovirus inhibitors, including capsid-specific monoclonal antibodies (Mabs) and nanobodies, have recently shown promising results. Several Mabs and nanobodies were found to inhibit norovirus replication using a human intestinal enteroid (HIE) culture system and/or could block norovirus attachment to histo-blood group antigen (HBGA) co-factors. In our pursuit to develop a single broad-spectrum norovirus therapeutic, we continued our analysis and development of a cross-reactive and HBGA interfering nanobody (NB26). To improve NB26 binding capacity and therapeutic potential, we conjugated NB26 onto a human IgG Fc domain (Fc-NB26). We confirmed that Fc-NB26 cross-reacts with genetically diverse GII genotype capsid protruding (P) domains (GII.8, GII.14, GII.17, GII.24, GII.26, and GII.NA1) using a direct enzyme-linked immunosorbent assay. Furthermore, X-ray crystallography structures of these P domains and structures of other GII genotypes reveal that the NB26 binding site is largely conserved, validating its broad reactivity. We showed that Fc-NB26 has ~100-fold higher affinity toward the norovirus P domain compared to native NB26. We also found that both NB26 and Fc-NB26 neutralize human norovirus replication in the HIE culture system. Furthermore, the mode of inhibition confirmed that like NB26, Fc-NB26 caused norovirus particle disassembly and aggregation. Overall, these new findings demonstrate that structural modifications to nanobodies can improve their therapeutic potential.IMPORTANCEDeveloping vaccines and antivirals against norovirus remains a challenge, mainly due to the constant genetic and antigenic evolution. Moreover, re-infection with genetically related and/or antigenic variants is not uncommon. We further developed our leading norovirus nanobody (NB26) that indirectly interfered with norovirus binding to HBGAs, by converting NB26 into a dimeric Fc-linked Nanobody (Fc-NB26). We found that Fc-NB26 had improved binding affinity and neutralization capacity compared with native NB26. Using X-ray crystallography, we showed this nanobody engaged highly conserved capsid residues among genetically diverse noroviruses. Development of such broadly reactive potent therapeutic nanobodies delivered as a slow-releasing prophylactic could be of exceptional value for norovirus outbreaks, especially for the prevention or treatment of severe acute gastroenteritis in high-risk groups such as the young, elderly, and immunocompromised.
Asunto(s)
Infecciones por Caliciviridae , Proteínas de la Cápside , Norovirus , Anticuerpos de Dominio Único , Norovirus/genética , Norovirus/efectos de los fármacos , Norovirus/inmunología , Humanos , Anticuerpos de Dominio Único/inmunología , Anticuerpos de Dominio Único/farmacología , Anticuerpos de Dominio Único/química , Proteínas de la Cápside/inmunología , Proteínas de la Cápside/metabolismo , Proteínas de la Cápside/química , Proteínas de la Cápside/genética , Infecciones por Caliciviridae/inmunología , Infecciones por Caliciviridae/virología , Infecciones por Caliciviridae/terapia , Antivirales/farmacología , Fragmentos Fc de Inmunoglobulinas/inmunología , Fragmentos Fc de Inmunoglobulinas/química , Anticuerpos Antivirales/inmunología , Reacciones Cruzadas , Cápside/metabolismo , Cápside/inmunología , Antígenos de Grupos Sanguíneos/metabolismo , Replicación Viral/efectos de los fármacos , Gastroenteritis/virología , Inmunoglobulina G/inmunología , Anticuerpos Monoclonales/inmunología , Anticuerpos Neutralizantes/inmunologíaRESUMEN
The ability to manipulate the self-assembly of proteins is essential to understanding the mechanisms of life and beneficial to fabricating advanced nanomaterials. Here, we report the transformation of the MS2 phage capsid from nanocages to nanotubes and then to nanotube hydrogels through simple point mutations guided by interfacial interaction redesign. We demonstrate that site 70, which lies in the flexible FG loop of the capsid protein (CP), is a "magic" site that can largely dictate the final morphology of assemblies. By varying the amino acid at site 70, with the aid of a cysteine-to-alanine mutation at site 46, we achieved the assembly of double-helical or single-helical nanotubes in addition to nanocages. Furthermore, an additional cysteine substitution on the surface of nanotubes mediated their cross-linking to form hydrogels with reducing agent responsiveness. The hierarchical self-assembly system allowed for the investigation of morphology-related immunogenicity of MS2 CPs, which revealed dramatic differences among nanocages, nanotubes, and nanotube hydrogels in terms of immune response types, antibody levels and T cell functions. This study provides insights into the assembly manipulation of protein nanomaterials and the customized design of nanovaccines and drug delivery systems.
Asunto(s)
Proteínas de la Cápside , Cápside , Hidrogeles , Nanotubos , Hidrogeles/química , Nanotubos/química , Proteínas de la Cápside/química , Proteínas de la Cápside/inmunología , Proteínas de la Cápside/genética , Cápside/química , Cápside/inmunología , Levivirus/química , Levivirus/inmunología , Levivirus/genética , Animales , Nanoestructuras/química , Ratones , Modelos MolecularesRESUMEN
BACKGROUND: Detection of viruses by host pattern recognition receptors induces the expression of type I interferon (IFN) and IFN-stimulated genes (ISGs), which suppress viral replication. Numerous studies have described HIV-1 as a poor activator of innate immunity in vitro. The exact role that the viral capsid plays in this immune evasion is not fully understood. RESULTS: To better understand the role of the HIV-1 capsid in sensing we tested the effect of making HIV-1 by co-expressing a truncated Gag that encodes the first 107 amino acids of capsid fused with luciferase or GFP, alongside wild type Gag-pol. We found that unlike wild type HIV-1, viral particles produced with a mixture of wild type and truncated Gag fused to luciferase or GFP induced a potent IFN response in THP-1 cells and macrophages. Innate immune activation by Gag-fusion HIV-1 was dependent on reverse transcription and DNA sensor cGAS, suggesting activation of an IFN response by viral DNA. Further investigation revealed incorporation of the Gag-luciferase/GFP fusion proteins into viral particles that correlated with subtle defects in wild type Gag cleavage and a diminished capacity to saturate restriction factor TRIM5α, likely due to aberrant particle formation. We propose that expression of the Gag fusion protein disturbs the correct cleavage and maturation of wild type Gag, yielding viral particles that are unable to effectively shield viral DNA from detection by innate sensors including cGAS. CONCLUSIONS: These data highlight the crucial role of capsid in innate evasion and support growing literature that disruption of Gag cleavage and capsid formation induces a viral DNA- and cGAS-dependent innate immune response. Together these data demonstrate a protective role for capsid and suggest that antiviral activity of capsid-targeting antivirals may benefit from enhanced innate and adaptive immunity in vivo.
Asunto(s)
VIH-1 , Inmunidad Innata , Nucleotidiltransferasas , Productos del Gen gag del Virus de la Inmunodeficiencia Humana , VIH-1/inmunología , VIH-1/genética , VIH-1/fisiología , Humanos , Productos del Gen gag del Virus de la Inmunodeficiencia Humana/genética , Productos del Gen gag del Virus de la Inmunodeficiencia Humana/inmunología , Productos del Gen gag del Virus de la Inmunodeficiencia Humana/metabolismo , Nucleotidiltransferasas/genética , Nucleotidiltransferasas/metabolismo , Factores de Restricción Antivirales , Macrófagos/inmunología , Macrófagos/virología , Proteínas de Motivos Tripartitos/genética , Proteínas de Motivos Tripartitos/metabolismo , Ubiquitina-Proteína Ligasas/genética , Ubiquitina-Proteína Ligasas/metabolismo , Células THP-1 , Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Proteínas Portadoras/inmunología , Evasión Inmune , Cápside/metabolismo , Cápside/inmunología , Replicación Viral , Virión/metabolismo , Virión/genética , Virión/inmunología , Interacciones Huésped-Patógeno/inmunología , ADN Viral/genética , Línea CelularRESUMEN
Recombinant adeno-associated virus (rAAV) vectors appear, more than ever, to be efficient viral vectors for in vivo gene transfer as illustrated by the approvals of 7 drugs across Europe and the United States. Nevertheless, preexisting immunity to AAV capsid in humans remains one of the major limits for a successful clinical translation. Whereas a preexisting humoral response to AAV capsid is well documented, the prevalence of preexisting capsid-specific T cell responses still needs to be studied and characterized. In this study, we investigated the prevalence of AAV-specific circulating T cells toward AAV2, 4, 5, 8, 9, and rh10 in a large cohort of healthy donors using the standard IFNγ ELISpot assay. We observed the highest prevalence of preexisting cellular immunity to AAV9 serotype followed by AAV8, AAV4, AAV2, AAVrh10, and AAV5 independently of the donors' serological status. An in-depth analysis of T cell responses toward the 2 most prevalent serotypes 8 and 9 shows that IFNγ secretion is mainly mediated by CD8 T cells for both serotypes. A polyfunctional analysis reveals different cytokine profiles between AAV8 and AAV9. Surprisingly, no IL-2 secretion was mediated by anti-AAV9 immune cells suggesting that these cells may rather be exhausted or terminally differentiated than cytotoxic T cells. Altogether, these results suggest that preexisting immunity to AAV may vary depending on the serotype and support the necessity of using multiparametric monitoring methods to better characterize anticapsid cellular immunity and foresee its impact in rAAV-mediated clinical trials.
Asunto(s)
Proteínas de la Cápside , Dependovirus , Vectores Genéticos , Inmunidad Celular , Humanos , Dependovirus/genética , Dependovirus/inmunología , Proteínas de la Cápside/inmunología , Proteínas de la Cápside/genética , Vectores Genéticos/genética , Voluntarios Sanos , Cápside/inmunología , Linfocitos T CD8-positivos/inmunología , Interferón gamma/metabolismo , Adulto , Serogrupo , Masculino , Femenino , Citocinas/metabolismo , Linfocitos T/inmunologíaRESUMEN
The aim of this paper is to develop and investigate a novel mathematical model of the dynamical behaviors of chronic hepatitis B virus infection. The model includes exposed infected hepatocytes, intracellular HBV DNA-containing capsids, uses a general incidence function for viral infection covering a variety of special cases available in the literature, and describes the interaction of cytotoxic T lymphocytes that kill the infected hepatocytes and the magnitude of B-cells that send antibody immune defense to neutralize free virions. Further, one time delay is incorporated to account for actual capsids production. The other time delays are used to account for maturation of capsids and free viruses. We start with the analysis of the proposed model by establishing the local and global existence, uniqueness, non-negativity and boundedness of solutions. After defined the threshold parameters, we discuss the stability properties of all possible steady state constants by using the crafty Lyapunov functionals, the LaSalle's invariance principle and linearization methods. The impacts of the three time delays on the HBV infection transmission are discussed through local and global sensitivity analysis of the basic reproduction number and of the classes of infected states. Finally, an application is provided and numerical simulations are performed to illustrate and interpret the theoretical results obtained. It is suggested that, a good strategy to eradicate or to control HBV infection within a host should concentrate on any drugs that may prolong the values of the three delays.
Asunto(s)
Inmunidad Adaptativa , Cápside , Simulación por Computador , Virus de la Hepatitis B , Hepatitis B Crónica , Hepatocitos , Conceptos Matemáticos , Hepatocitos/inmunología , Hepatocitos/virología , Virus de la Hepatitis B/inmunología , Humanos , Cápside/inmunología , Inmunidad Adaptativa/inmunología , Hepatitis B Crónica/inmunología , Hepatitis B Crónica/virología , Hepatitis B Crónica/transmisión , Modelos Inmunológicos , Linfocitos T Citotóxicos/inmunología , Número Básico de Reproducción/estadística & datos numéricos , Linfocitos B/inmunología , ADN Viral/inmunología , Modelos BiológicosRESUMEN
The versatile potential of bacteriophage MS2-derived virus-like particles (VLPs) in medical biotechnology has been extensively studied during the last 30 years. Since the first reports showing that MS2 VLPs can be produced at high yield and relatively easily engineered, numerous applications have been proposed. Particular effort has been spent in developing MS2 VLPs as protective capsules and delivery platforms for diverse molecules, such as chemical compounds, proteins and nucleic acids. Among these, two are particularly noteworthy: as scaffolds displaying heterologous epitopes for vaccine development and as capsids for encapsulation of foreign RNA. In this review, we summarize the progress in developing MS2 VLPs for these two areas.
Hollow, nanosized protein particles have many potential uses. If they can be appropriately engineered, they may for example be able to carry therapeutic cargoes to diseased cells or be used as a vaccine where appropriate antigens are mounted on their external surface. Many viruses offer a ready-made protein particle, the capsid, which can be made hollow by exclusion of the viral genetic material. MS2 is a virus that targets bacteria a bacteriophage which is well characterized and has been developed over many years for a number of applications. It has particular promise for development as a vaccine and for RNA delivery, both of which are reviewed here.
Asunto(s)
Levivirus , Levivirus/química , Levivirus/inmunología , Humanos , Animales , Vacunas de Partículas Similares a Virus/inmunología , Vacunas de Partículas Similares a Virus/química , ARN/química , Cápside/química , Cápside/inmunologíaRESUMEN
Aim: To develop an assay format for detection of total anti-adeno-associated virus 2 (AAV2) antibodies with low capsid material consumption. Methods: An immune complex (IC) assay format was developed. The format is based on the formation of ICs in solution and their subsequent detection using an anti-AAV2 antibody for capture and an antibody against the study species IgG for detection. Results: The feasibility of the IC assay for detection of preexisting and treatment-emergent anti-AAV2 antibodies was demonstrated in cynomolgus monkey and human serum samples, including samples from a preclinical study with AAV2-based therapies. Conclusion: The presented IC assay is an easy-to-perform total anti-AAV2 antibody assay that requires a small amount of unlabeled capsid material and provides an intrinsic specificity control.
[Box: see text].
Asunto(s)
Anticuerpos Antivirales , Dependovirus , Macaca fascicularis , Humanos , Animales , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Dependovirus/inmunología , Dependovirus/genética , Cápside/inmunología , Complejo Antígeno-Anticuerpo/inmunología , Complejo Antígeno-Anticuerpo/sangreRESUMEN
A critical determinant for early post-entry events, the HIV-1 capsid (CA) protein forms the conical core when it rearranges around the dimeric RNA genome and associated viral proteins. Although mutations in CA have been reported to alter innate immune sensing of HIV-1, a direct link between core stability and sensing of HIV-1 nucleic acids has not been established. Herein, we assessed how manipulating the stability of the CA lattice through chemical and genetic approaches affects innate immune recognition of HIV-1. We found that destabilization of the CA lattice resulted in potent sensing of reverse transcription products when destabilization per se does not completely block reverse transcription. Surprisingly, due to the combined effects of enhanced reverse transcription and defects in nuclear entry, two separate CA mutants that form hyperstable cores induced innate immune sensing more potently than destabilizing CA mutations. At low concentrations that allowed the accumulation of reverse transcription products, CA-targeting compounds GS-CA1 and lenacapavir measurably impacted CA lattice stability in cells and modestly enhanced innate immune sensing of HIV. Interestingly, innate immune activation observed with viruses containing unstable cores was abolished by low doses of lenacapavir. Innate immune activation observed with both hyperstable and unstable CA mutants was dependent on the cGAS-STING DNA-sensing pathway and reverse transcription. Overall, our findings demonstrate that CA lattice stability and reverse transcription are finely balanced to support reverse transcription and minimize cGAS-STING-mediated sensing of the resulting viral DNA. IMPORTANCE: In HIV-1 particles, the dimeric RNA genome and associated viral proteins and enzymes are encased in a proteinaceous lattice composed of the viral capsid protein. Herein, we assessed how altering the stability of this capsid lattice through orthogonal genetic and chemical approaches impacts the induction of innate immune responses. Specifically, we found that decreasing capsid lattice stability results in more potent sensing of viral reverse transcription products, but not the genomic RNA, in a cGAS-STING-dependent manner. The recently developed capsid inhibitors lenacapavir and GS-CA1 enhanced the innate immune sensing of HIV-1. Unexpectedly, due to increased levels of reverse transcription and cytosolic accumulation of the resulting viral cDNA, capsid mutants with hyperstable cores also resulted in the potent induction of type I interferon-mediated innate immunity. Our findings suggest that HIV-1 capsid lattice stability and reverse transcription are finely balanced to minimize exposure of reverse transcription products in the cytosol of host cells.
Asunto(s)
Proteínas de la Cápside , Cápside , VIH-1 , Inmunidad Innata , Proteínas de la Membrana , Nucleotidiltransferasas , Transcripción Reversa , VIH-1/genética , VIH-1/inmunología , Humanos , Proteínas de la Membrana/metabolismo , Proteínas de la Membrana/genética , Nucleotidiltransferasas/metabolismo , Nucleotidiltransferasas/genética , Proteínas de la Cápside/genética , Proteínas de la Cápside/metabolismo , Proteínas de la Cápside/inmunología , Cápside/metabolismo , Cápside/inmunología , Transducción de Señal , Células HEK293 , Infecciones por VIH/virología , Infecciones por VIH/inmunología , Infecciones por VIH/genética , ARN Viral/genética , ARN Viral/metabolismoRESUMEN
Los problemas virales reducen los rendimientos y la calidad del tubérculo semilla en cultivos de papa de todo el mundo. Esta investigación se planteó con el fin de evaluar los niveles de incidencia de potyvirus en diez de las principales regiones cultivadoras de papa de los departamentos de Antioquia, Boyacá, Cundinamarca y Nariño (Colombia), y las características genotípicas del virus Y de la papa (Potato virus Y, PVY), seleccionado por ser el potyvirus más limitante de este cultivo. Para la evaluación de la incidencia se utilizaron pruebas de Elisa con anticuerpos que reconocen epítopes comunes a los potyvirus, mientras que las pruebas moleculares incluyeron el análisis filogenético de secuencias parciales del gen de la cápside viral de 33 aislamientos, así como la secuenciación de una porción de los extremos 5´ y 3´del genoma de dos cepas colombianas de este virus. Los resultados confirmaron la presencia de potyvirus en los cultivos de los cuatro departamentos evaluados, con una incidencia promedio del 72%, siendo este nivel superior al 56% en todas las zonas evaluadas. Los análisis moleculares del PVY, permitieron asociar las cepas colombianas estudiadas con las razas PVYN y la variante PVYNTN, esta última responsable de la enfermedad conocida en el mundo como PTNRD (Potato tuber necrotic ringspot disease).
Potato viruses are responsible for significant reductions in seed quality and crop yields around the world. In this study, we evaluate the levels of incidence of potyvirus in ten potato growing regions of Colombia from the provinces of Antioquia, Boyacá, Cundinamarca and Nariño. As PVY is the most limiting potyvirus in potato farming, a molecular characterization of Colombian PVY strains was also performed. Incidence was evaluated by ELISA using general potyvirus antibodies. Phylogenetic analysis were made on the partial sequence of the capsid gene from 33 isolates. A portion of the 5´ and 3' genome ends was obtained from two Colombian strains. Results confirmed the presence of potyvirus in the four provinces with an average incidence of 72%. The lowest incidence value was 56%. Molecular analysis clustered all Colombian isolates with strains PVYN and PVYNTN, the latter responsible for the disease known as PTNRD (Potato tuber necrotic ringspot disease).
Asunto(s)
Potyvirus/aislamiento & purificación , Potyvirus/enzimología , Potyvirus/fisiología , Potyvirus/genética , Potyvirus/inmunología , Potyvirus/metabolismo , Potyvirus/patogenicidad , Potyvirus/química , Potyvirus/ultraestructura , Cápside/fisiología , Cápside/inmunología , Cápside/microbiología , Cápside/parasitología , Cápside/patología , Cápside/químicaRESUMEN
Acute human parvovirus B19 infection is followed by an antibody response to the structural proteins of the viral capsid (VP1 and VP2). We used 80 sera collected from 58 erythema infectiosum and 6 transient aplastic crisis patients to test IgM and IgG antibodies against these two proteins in an immunofluorescence assay (IFA) using Sf9 cells infected with recombinant baculovirus expressing either VP1 or VP2 antigen. Although less sensitive than IgM capture enzyme immunoassay using native antigen (MACEIA), we could detect anti-VP1 or anti-VP2 IgM antibodies by IFA in 49 patients with acute infection (76.6 percent). Detection of IgG anti-VP1 and anti-VP2 by IFA, however, was as sensitive as IgG detection by indirect enzyme immunoassay. By applying IgG avidity IFA to sera of the 15 IgM IFA negative patients we were able to confirm acute infection in further 12 cases by IFA. Overall, acute infection was confirmed by IFA in 61 (95.3 percent) of the 64 patients
Asunto(s)
Humanos , Niño , Adolescente , Adulto , Anticuerpos Antivirales/aislamiento & purificación , Cápside/inmunología , Infecciones por Parvoviridae/inmunología , Parvovirus B19 Humano/aislamiento & purificación , Anticuerpos Antivirales/sangre , Afinidad de Anticuerpos/inmunología , Cápside/sangre , Eritema Infeccioso/diagnóstico , Eritema Infeccioso/inmunología , Técnica del Anticuerpo Fluorescente , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Inmunoglobulina M/sangre , Inmunoglobulina M/inmunología , Infecciones por Parvoviridae/diagnósticoRESUMEN
El cáncer cervicouterino representa un grave problema de salud pública, debido a la asociación de la neoplasia con el virus del papiloma humano; actualmente se realizan estudios usados estrategias dirigidas a combatir este patógeno, mediante vacunas, que podrían ser de gran utilidad para el control de la progresión de la enfermedad. El estudio tanto de la inmunología humoral como celular ha servido para el desarrollo de vcunas. Así, la utilización de partículas virales sintéticas para el estudio de anticuerpos neutralizantes y el uso de proteínas tempranas virales, entre otras, para la inducción de inmunidad mediada por células, han sido la pauta para realizar estudios que dirijan la respuesta inmune para prevenir la infección celular tanto hacia células infectadas no transformadas como hacia células transformadas viralmente con resultados favorables
Asunto(s)
Papiloma/inmunología , Papiloma/prevención & control , Papillomaviridae/inmunología , Papillomaviridae/patogenicidad , Vacunas Virales/uso terapéutico , Neoplasias del Cuello Uterino/inmunología , Neoplasias del Cuello Uterino/prevención & control , Neoplasias del Cuello Uterino/virología , Antígenos de Histocompatibilidad Clase I , Antígenos de Histocompatibilidad Clase II , Antígenos Virales de Tumores , Cápside/inmunologíaRESUMEN
1. cDNA recombinants containing the VP3 and VP1 sequences of foot-and-mouth disease virus were isolated and the VP3-VP1 sequence was reconstructed. 2. The reconstructed VP3-VP1 sequence was subcloned into expression vector pEX31b and a fusion protein of about 62,000 Da was expressed. 3. When injected into mice, the fusion protein was able to elicit the production of antibodies that recognized viral VP1 and VP3. 4. Antibodies present in sera from mice immunized with VP3-VP1 protein did not neutralize the foot-and-mouth disease virus in vitro
Asunto(s)
Animales , Ratones , Anticuerpos Antivirales/biosíntesis , Aphthovirus/genética , Escherichia coli/genética , Proteínas Virales de Fusión/aislamiento & purificación , Aphthovirus/inmunología , Western Blotting , Cápside/genética , Cápside/inmunología , Cápside/aislamiento & purificación , Ensayo de Inmunoadsorción Enzimática , Epítopos/inmunología , Pruebas de Neutralización , Proteínas Virales de Fusión/genética , Proteínas Virales de Fusión/inmunologíaRESUMEN
El rotavirus es uno de los agentes etiológicos más comunes de la diarrea aguda de la infancia. La compresión de los mecanismos inmunológicos involucrados en las enfermedades por rotavirus incluso el conocimiento de las variaciones antigénicas, estacionales y geográficas pueden ser cruciales para el desarrollo de la vacuna. Un anticuerpo monoclonal, basado en ELISA, específico para el dominio antigénico sobre la cápside exterior proteica VP7, ha sido desarrollado y usado ampliamente durante los últimos años. Estudiamos la epidemiología del rotavirus VP7, causante de diarrea en niños que consultaron en los dos hospitales principales de Mendoza, Argentina, durante un período de 20 meses. Fueron identificados 227 casos de diarrea, 45 de los cuales (20 por ciento) fueron rotavirus positivas. Pudimos determinar el serotipo de 43 virus (96 por ciento), 42 tipo VP7 y 1 tipo VP7-3. Este último fue detectado hacia el final del segundo año representando posiblemente un tipo VP7 nuevo, que llegaba. Se identificaron 3 patrones electroforéticos, dos correspondientes a la epidemia de tipo VP7 en Mendoza, parecían caracterizados por un patrón relativamente homogéneo de circulación con fuerte predominancia del virus VP7-tipo 1,por lo menos durante el período estudiado de 20 meses, en contraste con lo que se ha informado en ciudades más grandes y cosmopolitas, tales como Buenos Aires
Asunto(s)
Humanos , Masculino , Femenino , Recién Nacido , Lactante , Preescolar , Anticuerpos Antivirales , Cápside/inmunología , Diarrea/microbiología , Proteínas Virales/inmunología , Rotavirus/inmunología , Enfermedad Aguda , Argentina/epidemiología , Diarrea/epidemiología , Electroforesis en Gel de Poliacrilamida , Ensayo de Inmunoadsorción Enzimática , Heces/microbiología , Estudios Prospectivos , Rotavirus/clasificaciónRESUMEN
El objetivo de este trabajo es demostrar la presencia de proteínas de virus papilomas humano (HPV) en biopsias de cuello uterino diagnosticadas histológicamente como cervicopatías de origen viral. Se escogieron 38 biopsias cervicales que cumplían con los criterios mencionados por Toki y Yajima para diagnóstico de HPV. Las biopsias provienen de archivos de placas del programa de detección de cáncer cérvico-uterino de las áreas Norte y Oriente de Santiago. Se empleó la técnica de inmunoperoxidasa usando el método ABC (complejo avidina-biotina-peroxidasa), utilizando como anticuerpo primario, uno policlonal diluido a 1:200, que reacciona con todas las variedades de virus papiloma. Veinte de las 38 biopsias (52,9%) presentan antígenos virales en núcleo de las capas superficiales del epitelio escamoso, en cantidad suficiente como para ser reconocidos por la sensibilidad del método. Este porcentaje es comparable a lo descrito en la literatura y que varía entre un 40% y un 62%